Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ANGLE plc ( (GB:CLBX) ) has provided an announcement.
CelLBxHealth plc announced a major international expert consensus highlighting the clinical relevance of circulating tumor cell (CTC) analysis in cancer management, with the Parsortix® platform identified as a leading next-generation technology. The consensus, published in the European Journal of Cancer, suggests that CTCs provide unique insights not captured by circulating tumor DNA and are expected to become routine in clinical practice within five years, supporting their use in metastatic cancer. This strengthens the foundation for clinical adoption of CTC-based technologies, aligning with CelLBxHealth’s mission to advance precision oncology. Additionally, the company is seeking to raise approximately £6 million to support its operations and engage with shareholders and potential investors.
The most recent analyst rating on (GB:CLBX) stock is a Sell with a £2.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.
Spark’s Take on GB:CLBX Stock
According to Spark, TipRanks’ AI Analyst, GB:CLBX is a Underperform.
The overall stock score reflects significant financial challenges and bearish technical indicators. ANGLE plc is struggling with declining revenues, persistent losses, and liquidity issues. The technical analysis indicates a strong downtrend, and valuation metrics are unfavorable with a negative P/E ratio. Despite some positive developments in pharma collaborations, the need for additional funding and adverse market conditions weigh heavily on the stock’s outlook.
To see Spark’s full report on GB:CLBX stock, click here.
More about ANGLE plc
CelLBxHealth plc is a global precision circulating tumor cell (CTC) intelligence company specializing in innovative CTC solutions for research, drug development, and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and integrates with existing laboratory instruments for comprehensive analysis, including whole-cell imaging, proteomic profiling, and genomic workflows. The company focuses on product sales, lab-developed tests, and laboratory services, with commercial activities centered on accelerating Parsortix platform adoption and consumable sales through partnerships.
Average Trading Volume: 2,500,396
Technical Sentiment Signal: Sell
Current Market Cap: £7.74M
Find detailed analytics on CLBX stock on TipRanks’ Stock Analysis page.